Biosimilars And Follow-On Biologics Market



Biosimilars And Follow-On Biologics Market
Biosimilars And FollowOn Biologics Market
Share, Global Trends,
Analysis, Research, Report,
Segmentation and Forecast,
Future Market Insights
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage
Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Subscription Information
For detailed subscription information please contact
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]
Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report Description
Biosimilars is defined as a type of biological product that is similar to another drug, which
has already been licensed (approved) by the US FDA or European Medicines Agency. Due
to their high degree of similarity with the biological reference product, they have no
clinically evidenced and meaningful differences from the reference product in terms of
quality, safety or efficacy. These drugs are also coined as follow-on biologics and are
mostly derived from biological sources such as bacterium and yeast. The constitution of
the biosimilar drugs can be either small molecules such as human insulin or
erythropoietin, or complex molecules such as monoclonal antibodies. Biosimilars are
increasing gaining prominence given the loss of exclusivity of big branded drugs. In
Europe, biosimilars can be marketed through independent applicant following expiry of
patent and market exclusivity periods of the reference product. A good example for this is
Pfizer acquisition of Hospira, to gain access to the latter’s attractive biosimilars portfolio.
Regulatory harmonization, naming and labelling, innovative licensure norms and route to
market for the biosimilar drugs are issues expected to gain attention and traction from
big drug makers in the forthcoming years.
Biosimilars and Follow-on Biologics Market: Drivers and Restraints
Drivers for the biosimilars market include big brand name drugs losing patent extensions,
cuts in healthcare costs across nations, forming of incentivized pricing policies by
companies in order to access high growth pharmerging markets and good development
in pharmacovigilance procedures across the globe. Other factors increasing the demand
for biosimilar drugs include rising disease incidences across the globe and better access
to healthcare for all nations.
Report Description
Request free sample Report:
Restraints for the market include constraints in developing and registering biosimilar
drugs and the complexity in the manufacturing processes. The drugs are difficult to verify
and have to undergo complex regulations. Further, the drugs are different from each
other due to variability in raw material and in the manufacturing process, which is
expected to deter the future development of biosimilar drugs. There are also risks in
having an increase in the versions of an identical biosimilar drug.
Biosimilars and Follow-on Biologics Market: Segmentation
Biosimilars and Follow-on Biologics Market can be segmented into these following ways:
• Segmentation by product class
• epoetins;
• filgrastims;
• insulins;
• growth hormones;
• alfa interferons;
Report Description
• monoclonal antibodies;
• beta interferons;
• follitropins;
• low-molecular-weight heparins (LMWH).
• Segmentation by application
• Rheumatoid arthritis
• Anemia
• Cancer
• Diabetes
• Others
• Segmentation by regions
Request for TOC:
Report Description
Biosimilars and Follow-on Biologics Market: Overview
Biosimilar market is expected to gain prominence over the forthcoming years due to
leading biologic drugs expected to lose exclusivity over the next seven years. Further,
biosimilar drugs, once formed, are expected to generate cost savings for the patient
population. Competition is expected to be limited in the market as the drugs are
expected to be formed using various types of innovative technologies. Biosimilars may
generate smaller savings for drug makers because of their complexity as well as
regulatory challenges of getting FDA approvals.
Biosimilars and Follow-on Biologics Market: Region-wise Outlook
Depending on geographic regions, biosimilar drug market is segmented into seven key
regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific,
Japan, and Middle East & Africa.
In terms of geography, Europe dominates the market, followed by Asia-Pacific. However,
rising technological advancement in healthcare and systematic drug review process will
drive the markets over North America, Japan and other regions. Europe dominates the
biosimilars market driven by technically advanced healthcare infrastructure and high
patient awareness & regulatory harmonization. Increasing funding for development of
biosimilar drugs, availability of high-quality research infrastructure and strategies
developed by drug makers to restrict entry of new players. Emerging markets include
Eastern European countries followed by countries in Eastern Africa.
Report Description
Rising disease incidences in these countries is expected to prove favorable for the growth
of the biosimilar drug market.
Browse full report:
Biosimilars and Follow-on Biologics Market: Key Players
Some of the key players in biosimilar market are Pfizer Inc. (AC. Hospira), Sandoz
International GmbH, , Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories,
Biocon Limited, Mylan, Inc. , Amgen, Celltrion Inc., Roche Diagnostics, and Merck KGaA.
Thank You!
To know more about us, please visit our website:
For sales queries or new topics email us on:
[email protected]
For other queries contact: Mr. Sudip Saha
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705

Similar documents

Global Mobile Tracking Solution Market

Global Mobile Tracking Solution Market Mobile tracking solution enables user to get real time update on the position of mobile assets. GPS devices and RFID tags when attached with equipment and assets ensure efficient mobile tracking. Handheld scanners and mobile phones can also be used to track mobile assets. Mobile traction solution find their application in medical asset tracking, mobile industrial generator tracking, construction assets tracking, military assets tracking, wild-life and conservation, and shipping & container tracking etc.

More information

Global Business Email Market

Global Business Email Market Electronic mail solution or preferably called email solution, specializes in the day-to-day management of your email services which allows users to remain focused on more critical operations of business. Email solution providers make it simple for organizations and enterprises to communicate across as well as get tasks implemented by offering a reliable, business suited email software to meet such needs. The business email solution offers multiple layers of premium virus and spam protection and keep hosted email advertisement free. Business organizations across the globe are now steadily adopting the strategy of migrating their email to cloud to reduce costs. The enumeration of organizations migrating to cloud-based email and collaboration services has continued to build over the past few years, where previously small and medium business (SMB) were the key end-users of business email solutions, now larger organizations are aggressively moving to the cloud. The current number of email users worldwide in 2015 is recognized to be about 2.6 billion, and this figure is expected to grow at a healthy CAGR till 2026. While total worldwide email traffic estimated to about 200 billion email per day in 2015, the corporate emails represent the major share of this total value.

More information